Navigation Links
Strides Arcolab makes strategic investment in Oncobiologics, Inc., USA
Date:7/16/2014

BANGALORE, India and CRANBURY, N.J., July 16, 2014 /PRNewswire/ -- Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc., a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.

The investment is part of Strides' strategy to fund promising biopharma companies with high quality scientific management and proprietary approaches to developments that confer significant time and cost advantages.

Financial terms were not disclosed.

"The investments by Strides Arcolab represent important milestones for Oncobiologics. Strides Arcolab is a long-term strategic partner that provides both financial strength and a proven track-record of successful business ventures. We look forward to their support and guidance as we continue to execute Oncobiologics' business and technical plans," said Oncobiologics Founder & CEO, Pankaj Mohan, Ph.D.  

Commenting on the development, Arun Kumar, Founder and Group CEO of Strides Arcolab said, "Strides Arcolab is proud to announce this strategic partnership with Oncobiologics. After significant due diligence, it is evident that their success to-date in meeting technical milestones is an indicator of the solid team and business model they have constructed. We look forward to sharing in Oncobiologics' future successes."

About Strides Arcolab Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. Strides has made significant investments in its own Bio
'/>"/>

SOURCE Oncobiologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Molecular eat now signal makes cells devour dying neighbors
2. ITRA Global Report Makes the Case That Bio Tech Companies Should Consider Tucson, Arizona for Relocation or Expansion
3. ExakTime Makes 2013 Inc. 500
4. 5000 List for the Fourth Time
5. NeriumAD Makes Headlines at an Emmy Gifting Suite
6. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
7. Lawrence Livermore engineering team makes breakthrough in solar energy research
8. Pittsburgh Life Sciences Greenhouse Makes Strategic Adjustment To Put Laser Focus On 2013 Goals
9. The MedZilla.com Employment Report for July, 2013: Nation's Economy Makes Substantial, Demonstrable Improvements
10. Accel-KKR Makes Growth Equity Investment in Zinc Ahead, Leading Provider of Marketing Compliance Solutions for the Life Sciences Industry
11. Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... the delivery of product safety and pharmacovigilance services and software tools to pharmaceutical ... application, PRIMO Mobile by Allergan Japan. PRIMO Mobile is a mobile data intake ...
(Date:9/3/2015)... REDWOOD CITY, Calif. , Sept. 3, 2015 ... announced today that five abstracts highlighting the performance ... patients have been accepted for oral and poster ... of Lung Cancer,s 16th World Conference on Lung ... Cancer Center; the University of California, Davis; the ...
(Date:9/3/2015)...  StemProtein LLC, a leading manufacturer of stem ... Cell Technologies Inc., announced today that it appoints ... StemProtein. Silberg will help advance the Company,s patented ... Factors (SCFs), a significant consumer opportunity. ... biopharmaceutical industries with substantial executive level experience with ...
(Date:9/3/2015)... Michigan (PRWEB) , ... September 03, 2015 , ... ... to release its non-invasive hydration monitoring wearable early 2016. , The device, ... level using proprietary optical and electrical sensing technology. These sensors track trending ...
Breaking Biology Technology:November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2
... (Nasdaq: AMGN ) today announced that results ... trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX ... metastatic colorectal cancer (mCRC), respectively, were published online in ... "Both studies demonstrated that Vectibix administered with chemotherapy ...
... 4 Reportlinker.com announces that a new market ... Global Soft Tissue Allografts Industry ... report analyzes the worldwide markets for Soft Tissue ... Cartilage Allografts, Meniscus Allografts, and Tendon Allografts. The ...
... Inc., the U.S.-based group company of Shionogi & ... Drug Administration approval of the non-stimulant medication KAPVAY™ ... for the treatment of Attention Deficit Hyperactivity Disorder ... KAPVAY™ is the only formulation of clonidine hydrochloride ...
Cached Biology Technology:Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11Reportlinker Adds Global Soft Tissue Allografts Industry 2Reportlinker Adds Global Soft Tissue Allografts Industry 3Reportlinker Adds Global Soft Tissue Allografts Industry 4Reportlinker Adds Global Soft Tissue Allografts Industry 5Reportlinker Adds Global Soft Tissue Allografts Industry 6Reportlinker Adds Global Soft Tissue Allografts Industry 7Reportlinker Adds Global Soft Tissue Allografts Industry 8Reportlinker Adds Global Soft Tissue Allografts Industry 9Reportlinker Adds Global Soft Tissue Allografts Industry 10Reportlinker Adds Global Soft Tissue Allografts Industry 11Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 2Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 3Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 4Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 5Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 6
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... concern for enterprises, banks, government organizations, telecommunication and hospitals ... assets. Keys, identity badges, and numeric keypads are used ... the structure of palm and fingers of an individual, ... Hand geometry scanners with infrared light and reflectors can ...
(Date:9/2/2015)... , Sept. 2, 2015 Security ... concern for enterprises, banks, government organizations, telecommunications, hospitals, ... numeric keypads were previously being used to prevent ... of two-factor authentication, wherein individuals could gain access ... different components, such as hardware devices and numeric ...
(Date:9/2/2015)... 2, 2015 Biometric ... in a system which uses identical human characteristic ... vein, DNA and finger print. Increasing number of ... such system which provides high level of security. ... and tokens are vulnerable to attacks. Furthermore, Biometric ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... fish populations leaving them in danger of total collapse, ... measures in place to control fish stocks may not ... research, which is published in today's Nature, involved compiling ... non-exploited fish off the California coast. The research team ...
... Researchers from the University of Pennsylvania School of Veterinary Medicine ... of fish and mammals in the form of a primitive ... system. Their studies link the evolution of the adaptive ... fight infection, to the more primitive innate immunity in fish, ...
... Institut Pasteur has recently shown that the tuberculosis bacillus ... cells. This formidable pathogen is protected against even the ... may remain dormant for years. This discovery, published in ... fighting tuberculosis. Attempts to eradicate the bacillus entirely from ...
Cached Biology News:Commercial fishing causes dangerous fluctuations in fish populations 2'Killer' B cells demonstrate evolutionary link between fish and mammal immune systems 2'Killer' B cells demonstrate evolutionary link between fish and mammal immune systems 3Tuberculosis: The bacillus takes refuge in adipose cells 2
... surface is produced by a patented microwave ... giving more consistent, even cell attachment, increased ... attachment and growth uunder difficult conditions, including ... may provide a more ecominic alternative to ...
... array system, 100-240 V, uses multiplex suspension ... analysis of up to 100 proteins and ... suspension array is composed of up to ... may be conjugated with a unique reactant ...
... shaker flasks have three extra deep baffles ... to improve oxygen or gas transfer when ... long neck reduces splashing and is designed ... thickness provides the proper balance between mechanical ...
... Analysis of large numbers of samples may be ... system, which requires minimum operator attention. ... PowerStream software and interface CE 4900. The ... operates in Windows XP and Windows 98 and ...
Biology Products: